⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CGEM News
Cullinan Therapeutics, Inc. Common Stock
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
globenewswire.com
CGEM
Global Shared Services Market Forecast to 2035 by Component, Deployment, Service, End User, and Region | Cloud and Automation Propel 20.84% CAGR Toward $473 Billion
globenewswire.com
ACN
CGEM
CTSH
DDT
DXC
G
IBM
INFY
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
globenewswire.com
CGEM
Form 8-K
sec.gov
CGEM
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
globenewswire.com
CGEM
Form 8-K
sec.gov
CGEM
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
globenewswire.com
CGEM
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
globenewswire.com
CGEM
Form 8-K
sec.gov
CGEM
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
globenewswire.com
CGEM